ArticleScientific reports2025
Green synthesized zinc oxide nanoparticles with lemongrass essential oil for the development of an effective herbal mouthwash.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral pathogens contribute to dental caries and other infections affecting oral health. To address concerns related to the adverse effects of chemical mouthwashes like chlorhexidine (CHX), this study introduces a novel herbal mouthwash formulated with green-synthesized zinc oxide nanoparticles (ZnONPs) infused with Cymbopogon citratus essential oil (CEO). Unlike traditional formulations, this herbal mouthwash aims to offer a safer, eco-friendly alternative. Four formulations (F1-F4) with varying concentrations of CEOZnONPs were evaluated for in vitro antibacterial and anti-biofilm activities against Streptococcus mutans, Staphylococcus aureus, and Escherichia coli. The F4 formulation demonstrated superior antibacterial efficacy, with inhibition zones of 64.2 ± 2.6 mm for S. mutans, 43.6 ± 1.0 mm for S. aureus, and 31.8 ± 1.5 mm for E. coli, and achieved 97.12% biofilm inhibition of S. mutans. Additionally, in vivo toxicity was assessed using embryonic zebrafish, showing a high survival rate of 93% for F1 and 82% for F4 after 24 hours, compared to 65% for CHX, indicating lower toxicity. This preclinical study shows that the F4 formulation exhibited promising antibacterial and safety profiles, highlighting its potential as a safe, natural oral care product targeting diverse oral pathogens with reduced toxicity. Further research, including in vivo and clinical trials, is needed to validate its effectiveness and safety for regular dental care use. The herbal mouthwash formulated with CEOZnONPs demonstrates strong antibacterial and anti-biofilm effects with lower toxicity, making it a promising natural alternative for oral hygiene. Its safer profile compared to CHX may reduce side effects in patients, potentially enhancing compliance in oral care regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.